Annexon, Inc. (ANNX)
| Market Cap | 897.86M +381.4% |
| Revenue (ttm) | n/a |
| Net Income | -198.33M |
| EPS | -1.19 |
| Shares Out | 163.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,998,303 |
| Open | 5.41 |
| Previous Close | 5.31 |
| Day's Range | 5.29 - 5.47 |
| 52-Week Range | 1.85 - 7.18 |
| Beta | 1.22 |
| Analysts | Strong Buy |
| Price Target | 13.13 (+139.6%) |
| Earnings Date | May 7, 2026 |
About ANNX
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ANNX stock is "Strong Buy." The 12-month stock price target is $13.13, which is an increase of 139.60% from the latest price.
News
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammato...
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference
Annexon NASDAQ: ANNX President and CEO Doug Love outlined the company's late-stage pipeline and regulatory plans during a presentation at the Bank of America Healthcare Conference, highlighting upcomi...
Annexon Transcript: Bank of America Global Healthcare Conference 2026
The company highlighted differentiated complement pathway therapies for neuroinflammatory diseases, with late-stage programs in geographic atrophy and Guillain-Barré syndrome showing strong efficacy and safety. Commercial and regulatory strategies are advancing in both the U.S. and Europe, with additional pipeline progress in small molecule candidates.
Annexon initiated with a Neutral at Goldman Sachs
Goldman Sachs initiated coverage of Annexon (ANNX) with a Neutral rating and $7 price target Annexon is a clinical-stage biotechnology company developing therapeutics for neuroinflammatory diseases vi...
110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS
CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and n...
Annexon reports Q1 EPS (23c), consensus (30c)
“As we execute toward major milestones in 2026, we are sharply focused on our strategic priorities across the organization,” said Douglas Love, president and chief executive officer of Annexon (ANNX).
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA
Annexon Quarterly report: Q1 2026
Annexon has published its Q1 2026 quarterly earnings report on May 7, 2026.
Annexon Earnings release: Q1 2026
Annexon released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Annexon to Present at the Bank of America Securities Health Care Conference 2026
BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammato...
Annexon Proxy statement: Proxy filing
Annexon filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Annexon Proxy statement: Proxy filing
Annexon filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Annexon Slides: Corporate presentation
Annexon has posted slides in relation to its latest quarterly earnings report, which was published on April 27, 2026.
Annexon Proxy statement: Proxy filing
Annexon filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Annexon Transcript: 25th Annual Needham Virtual Healthcare Conference
2026 is set to be a milestone year, with anticipated regulatory filings and pivotal data readouts for late-stage programs in GBS, GA, and ANX1502. Vonaprument’s differentiated C1q-targeting approach in GA is advancing through a robust phase III trial, while GBS and ANX1502 programs are progressing toward key regulatory and clinical milestones.
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference
BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflamma...
Chardan sees positive read-through to Annexon’s vonaprument from Apellis deal
Biogen (BIIB) has agreed to acquire Apellis Pharmaceuticals (APLS) for $41 per share, bringing complement inhibitors Syfovre and Empaveli into its portfolio, with Syfovre’s $589M in 2025 sales viewed ...
Annexon files automatic mixed securities shelf
06:11 EDT Annexon (ANNX) files automatic mixed securities shelf
Annexon reports Q4 EPS (28c), consensus (32c)
“We’re energized by this defining period for Annexon (ANNX). Two decades of C1q and classical complement pathway research have enabled our bold mission of pioneering a new class of targeted…
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA
Annexon Earnings release: Q4 2025
Annexon released its Q4 2025 earnings on March 30, 2026, summarizing the period's financial results.
Annexon Annual report: Q4 2025
Annexon has published its Q4 2025 annual report on March 30, 2026.
Annexon Transcript: KOL event
Vonoprument targets C1q to preserve vision in GA, showing strong functional and structural benefits in phase II and a favorable safety profile. The phase III program is highly powered, globally aligned, and aims to deliver the first vision-preserving therapy for a large, underserved market.
Annexon Slides: KOL event
Annexon has posted slides in relation to its latest quarterly earnings report, which was published on March 18, 2026.
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflamma...